Top-News
Biotechnologie USA

BioMarin Pharmaceutical Inc Aktie

Aktie
WKN:  924801 ISIN:  US09061G1013 US-Symbol:  BMRN
55,90 €
-0,30 €
-0,53%
12:27:23 Uhr
Depot/Watchlist
Aktienanzahl *
190,38 Mio.
Marktkapitalisierung *
10,70 Mrd. €
Streubesitz
0,73%
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 22.08.2024
Weiter abwärts? Short handeln - Jetzt mit Hebel 10,65: MK17QZ
Werbung

BioMarin Pharmaceutical Inc News

01.05.25 - PR Newswire
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance PR Newswire
17.04.25 - PR Newswire
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET PR Newswire
02.04.25 - PR Newswire
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-​pqpz) in Adolescents with Phenylketonuria PR Newswire
20.03.25 - PR Newswire
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-​World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with ...
25.02.25 - PR Newswire
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA PR Newswire
24.02.25 - PR Newswire
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors PR Newswire
19.02.25 - PR Newswire
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance PR Newswire
05.02.25 - PR Newswire
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET PR Newswire
13.01.25 - PR Newswire
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court PR Newswire
06.01.25 - PR Newswire
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA PR Newswire
16.11.24 - PR Newswire
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
BioMarin Presents Real-​World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric ...
06.11.24 - PR Newswire
BioMarin to Participate in Three Upcoming Investor Conferences
BioMarin to Participate in Three Upcoming Investor Conferences PR Newswire
29.10.24 - PR Newswire
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook PR Newswire
16.10.24 - PR Newswire
BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET
BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET PR Newswire
18.09.24 - PR Newswire
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-​Related Quality of Life, Growth and Maintenance of Bone Strength in Children ...
04.09.24 - PR Newswire
BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance PR Newswire
04.09.24 - PR Newswire
BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time PR Newswire
29.08.24 - PR Newswire
BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY
BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY PR Newswire
21.08.24 - PR Newswire
BioMarin Announces New R&D and Business Development Leadership
BioMarin Announces New R&D and Business Development Leadership PR Newswire
19.08.24 - PR Newswire
BioMarin to Host 2024 Investor Day on September 4th in New York
BioMarin to Host 2024 Investor Day on September 4th in New York PR Newswire

Newssuche

Videos

newspaper
30.04.25 +3,37%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »